Can the future of ID escape the inertial dogma of its past? The exemplars of shorter is better and oral is the new IV
K Davar, D Clark, RM Centor… - Open Forum …, 2023 - academic.oup.com
Like all fields of medicine, Infectious Diseases is rife with dogma that underpins much
clinical practice. In this study, we discuss 2 specific examples of historical practice that have …
clinical practice. In this study, we discuss 2 specific examples of historical practice that have …
Pneumocystis jirovecii Pneumonia after Heart Transplantation: Two Case Reports and a Review of the Literature
C Burzio, E Balzani, S Corcione, G Montrucchio… - Pathogens, 2023 - mdpi.com
Post-transplant Pneumocystis jirovecii pneumonia (PcP) is an uncommon but increasingly
reported disease among solid organ transplantation (SOT) recipients, associated with …
reported disease among solid organ transplantation (SOT) recipients, associated with …
Low-dose trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia: a systematic review and meta-analysis
HB Huang, YB Zhu, DX Yu - Frontiers in Pharmacology, 2024 - frontiersin.org
Background The recommended standard treatment for Pneumocystis jirovecii pneumonia
(PJP) is high-dose trimethoprim-sulfamethoxazole (TMP-SMX)(15–20 mg/kg/d TMP) …
(PJP) is high-dose trimethoprim-sulfamethoxazole (TMP-SMX)(15–20 mg/kg/d TMP) …
Clinical characteristics and risk factors for late‐onset pneumocystis jirovecii pneumonia in kidney transplantation recipients
X Zhu, M Xie, J Fan, B Geng, G Fei, Q Zhou, H Wu… - Mycoses, 2024 - Wiley Online Library
Background Pneumocystis jirovecii pneumonia (PJP) is a common and troublesome
complication of kidney transplantation. In the era of prophylaxis, the peak incidence of PJP …
complication of kidney transplantation. In the era of prophylaxis, the peak incidence of PJP …
The Development and Evaluation of a Prediction Model for Kidney Transplant-Based Pneumocystis carinii Pneumonia Patients Based on Hematological Indicators
L Zhang, Y Liu, J Zou, T Wang, H Hu, Y Zhou, Y Lu… - Biomedicines, 2024 - mdpi.com
Background: This study aimed to develop a simple predictive model for early identification of
the risk of adverse outcomes in kidney transplant-associated Pneumocystis carinii …
the risk of adverse outcomes in kidney transplant-associated Pneumocystis carinii …
[HTML][HTML] Comparison of High-Dose versus Low-Dose Trimethoprim–Sulfamethoxazole for Treating Pneumocystis jirovecii Pneumonia among Hemodialysis Patients …
H Shuto, S Omori, K Hiramatsu, J Kadota… - Journal of Clinical …, 2024 - mdpi.com
Background: Hemodialysis patients are at high risk for developing Pneumocystis jirovecii
pneumonia (PJP), and trimethoprim–sulfamethoxazole (TMP–SMX) is the first-line agent for …
pneumonia (PJP), and trimethoprim–sulfamethoxazole (TMP–SMX) is the first-line agent for …
Prophylactic trimethoprim-sulfamethoxazole is safe in adult patients with primary central nervous system lymphoma receiving high-dose methotrexate
Q Xu, Z Li, T Ding, X Qiu, Z Wu - Annals of Hematology, 2024 - Springer
This retrospective study investigated the potential drug-drug interactions between
trimethoprim-sulfamethoxazole (TMP-SMZ) and high-dose methotrexate (HD-MTX) in adult …
trimethoprim-sulfamethoxazole (TMP-SMZ) and high-dose methotrexate (HD-MTX) in adult …
[HTML][HTML] Outcomes of low-dose trimethoprim-sulfamethoxazole treatment in patients with non-HIV pneumocystis pneumonia: A nationwide Japanese retrospective …
J Taniguchi, S Aso, T Jo, H Matsui, K Fushimi… - Infectious Diseases …, 2024 - Elsevier
Objectives Low-dose trimethoprim-sulfamethoxazole (TMP-SMX) may be a treatment option
for patients with Pneumocystis jirovecii pneumonia (PCP). However, its effectiveness in …
for patients with Pneumocystis jirovecii pneumonia (PCP). However, its effectiveness in …
[HTML][HTML] Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023
CM Rodríguez-Leal, C González-Corralejo… - Revista Española de …, 2024 - ncbi.nlm.nih.gov
Pneumonia is a multifaceted illness with a wide range of clinical manifestations, degree of
severity and multiple potential causing microorganisms. Despite the intensive research of …
severity and multiple potential causing microorganisms. Despite the intensive research of …